1. Home
  2. CALC vs HFBL Comparison

CALC vs HFBL Comparison

Compare CALC & HFBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • HFBL
  • Stock Information
  • Founded
  • CALC 2011
  • HFBL 1924
  • Country
  • CALC United States
  • HFBL United States
  • Employees
  • CALC N/A
  • HFBL N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • HFBL Savings Institutions
  • Sector
  • CALC Health Care
  • HFBL Finance
  • Exchange
  • CALC Nasdaq
  • HFBL Nasdaq
  • Market Cap
  • CALC 45.4M
  • HFBL 41.6M
  • IPO Year
  • CALC N/A
  • HFBL N/A
  • Fundamental
  • Price
  • CALC $3.11
  • HFBL $15.00
  • Analyst Decision
  • CALC Strong Buy
  • HFBL
  • Analyst Count
  • CALC 2
  • HFBL 0
  • Target Price
  • CALC $14.50
  • HFBL N/A
  • AVG Volume (30 Days)
  • CALC 46.6K
  • HFBL 1.9K
  • Earning Date
  • CALC 11-12-2025
  • HFBL 10-23-2025
  • Dividend Yield
  • CALC N/A
  • HFBL 3.60%
  • EPS Growth
  • CALC N/A
  • HFBL 35.20
  • EPS
  • CALC N/A
  • HFBL 1.47
  • Revenue
  • CALC N/A
  • HFBL $21,720,000.00
  • Revenue This Year
  • CALC N/A
  • HFBL N/A
  • Revenue Next Year
  • CALC N/A
  • HFBL N/A
  • P/E Ratio
  • CALC N/A
  • HFBL $10.22
  • Revenue Growth
  • CALC N/A
  • HFBL 10.10
  • 52 Week Low
  • CALC $1.42
  • HFBL $11.75
  • 52 Week High
  • CALC $5.65
  • HFBL $15.03
  • Technical
  • Relative Strength Index (RSI)
  • CALC 48.87
  • HFBL 78.49
  • Support Level
  • CALC $3.04
  • HFBL $14.00
  • Resistance Level
  • CALC $3.15
  • HFBL $14.86
  • Average True Range (ATR)
  • CALC 0.18
  • HFBL 0.12
  • MACD
  • CALC -0.03
  • HFBL 0.07
  • Stochastic Oscillator
  • CALC 21.74
  • HFBL 100.00

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

Share on Social Networks: